Healthcare provider profile · identity verified

Raul Otoman, MD

General Practice · HATILLO, PR · NPI 1316032840

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Gabapentin	Gabapentin	603	125
Levothyroxine Sodium	Levothyroxine Sodium	355	61
Metformin Hcl	Metformin Hcl	315	86
Atorvastatin Calcium	Atorvastatin Calcium	301	88
Clopidogrel	Clopidogrel Bisulfate	300	57
Simvastatin	Simvastatin	298	90
Sertraline Hcl	Sertraline Hcl	273	51
Famotidine	Famotidine	265	72
Losartan Potassium	Losartan Potassium	253	72
Hydrochlorothiazide	Hydrochlorothiazide	233	43
Lisinopril	Lisinopril	194	61
Montelukast Sodium	Montelukast Sodium	184	38
Donepezil Hcl	Donepezil Hcl	178	31
Omeprazole	Omeprazole	173	43
Tamsulosin Hcl	Tamsulosin Hcl	152	30
Glipizide	Glipizide	149	44
Amlodipine Besylate	Amlodipine Besylate	142	44
Isosorbide Mononitrate Er	Isosorbide Mononitrate	116	18
Synthroid	Levothyroxine Sodium	113	25
Risperidone	Risperidone	109	18
Pantoprazole Sodium	Pantoprazole Sodium	105	25
Alendronate Sodium	Alendronate Sodium	104	23
Clonazepam	Clonazepam	96	34
Cilostazol	Cilostazol	95	22
Furosemide	Furosemide	93	25
Metoprolol Succinate	Metoprolol Succinate	79	20
Finasteride	Finasteride	77	12
Trazodone Hcl	Trazodone Hcl	77	11
Quetiapine Fumarate	Quetiapine Fumarate	72	13
Lantus	Insulin Glargine,hum.Rec.Anlog	69	15
Carvedilol	Carvedilol	66	14
Enalapril Maleate	Enalapril Maleate	65	20
Azithromycin	Azithromycin	64	58
Rosuvastatin Calcium	Rosuvastatin Calcium	63	22
Advocate Syringes	Syringe And Needle,insulin,1ml	61	suppressed
Clotrimazole-Betamethasone	Clotrimazole/Betamethasone Dip	61	23
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	60	11
Prednisone	Prednisone	60	33
Glimepiride	Glimepiride	56	17
Haloperidol	Haloperidol	55	suppressed
Atenolol	Atenolol	54	21
Irbesartan	Irbesartan	49	suppressed
Temazepam	Temazepam	49	16
Memantine Hcl	Memantine Hcl	44	suppressed
Lorazepam	Lorazepam	40	suppressed
Humulin N	Insulin Nph Human Isophane	39	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	39	suppressed
Divalproex Sodium	Divalproex Sodium	38	suppressed
Sucralfate	Sucralfate	38	suppressed
Eliquis	Apixaban	37	suppressed
Nabumetone	Nabumetone	37	19
Spironolactone	Spironolactone	36	suppressed
Methylprednisolone	Methylprednisolone	33	12
Insulin Syringe	Syring-Needl,disp,insul,0.3 Ml	32	suppressed
Levofloxacin	Levofloxacin	32	28
Citalopram Hbr	Citalopram Hydrobromide	31	suppressed
Diclofenac Potassium	Diclofenac Potassium	30	11
Oxybutynin Chloride Er	Oxybutynin Chloride	30	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	29	12
Ciprofloxacin Hcl	Ciprofloxacin Hcl	29	26
Diclofenac Sodium	Diclofenac Sodium	29	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	29	24
Meloxicam	Meloxicam	28	22
Fenofibrate	Fenofibrate Nanocrystallized	27	suppressed
Metoprolol Tartrate	Metoprolol Tartrate	27	suppressed
Glipizide Er	Glipizide	25	suppressed
Buspirone Hcl	Buspirone Hcl	24	suppressed
Paroxetine Hcl	Paroxetine Hcl	24	suppressed
Anastrozole	Anastrozole	23	suppressed
Fenofibrate	Fenofibrate	23	suppressed
Duloxetine Hcl	Duloxetine Hcl	22	suppressed
Nifedipine Er	Nifedipine	22	suppressed
Raloxifene Hcl	Raloxifene Hcl	22	suppressed
Levetiracetam	Levetiracetam	21	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	20	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	20	suppressed
Alprazolam	Alprazolam	19	suppressed
Naproxen	Naproxen	19	14
Oxybutynin Chloride	Oxybutynin Chloride	19	suppressed
Pravastatin Sodium	Pravastatin Sodium	19	suppressed
Amiodarone Hcl	Amiodarone Hcl	18	suppressed
Baclofen	Baclofen	18	13
Bupropion Xl	Bupropion Hcl	18	suppressed
Ezetimibe	Ezetimibe	18	suppressed
Fluticasone Propionate	Fluticasone Propionate	18	suppressed
Hydralazine Hcl	Hydralazine Hcl	18	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	18	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	17	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	17	suppressed
Escitalopram Oxalate	Escitalopram Oxalate	17	suppressed
Candesartan-Hydrochlorothiazid	Candesartan/Hydrochlorothiazid	16	suppressed
Cephalexin	Cephalexin	16	14
Latanoprost	Latanoprost	16	suppressed
Permethrin	Permethrin	16	13
Betamethasone Dipropionate	Betamethasone Dipropionate	15	suppressed
Entresto	Sacubitril/Valsartan	15	suppressed
Pentoxifylline	Pentoxifylline	15	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Benztropine Mesylate	Benztropine Mesylate	13	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	13	suppressed
Dexamethasone	Dexamethasone	13	12
Diltiazem Hcl	Diltiazem Hcl	13	suppressed
Ibuprofen	Ibuprofen	13	suppressed
Meclizine Hcl	Meclizine Hcl	13	suppressed
Trueplus Insulin Syringe	Syringe And Needle,insulin,1ml	13	suppressed
Breo Ellipta	Fluticasone/Vilanterol	12	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	12	suppressed
Metronidazole	Metronidazole	12	suppressed
Mupirocin	Mupirocin	12	12
Dicyclomine Hcl	Dicyclomine Hcl	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Estazolam	Estazolam	11	suppressed
Insulin Syringe	Syringe-Needle,insulin,0.5 Ml	11	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	11	suppressed
Lactulose	Lactulose	11	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	11	suppressed
Mirtazapine	Mirtazapine	11	suppressed
Omega-3 Acid Ethyl Esters	Omega-3 Acid Ethyl Esters	11	suppressed
Tizanidine Hcl	Tizanidine Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error